key: cord-0917648-p1kdj7hj
authors: Choudhary, A.; Lerman, M.; Calianese, D.; Khan, S.; Hunt, J.; Nikaein, A.; Honnen, W.; Jaijyan, D. K.; Kalu, E.; Pinter, A.
title: Prior SARS-CoV2 infection in vaccinated solid organ transplant recipients induces potent neutralization responses against variants, including Omicron
date: 2022-02-15
journal: nan
DOI: 10.1101/2022.02.10.22270607
sha: 9c1d4d93c50ea5f3de653ca73b4106e77c5c6e27
doc_id: 917648
cord_uid: p1kdj7hj

Factors affecting functional antibody responses in solid organ transplant recipients (SOTRs) to current SARS-CoV2 vaccines are not well understood. Here, we measured vaccine-induced neutralizing activities against the D614G-CoV2 baseline virus and eight variants, including Omicron, in a panel of CoV2 infected- (n=13) and uninfected- (n=63) vaccinated kidney and heart transplant recipients. In the CoV2 uninfected-vaccinated subset, only 19% and 35% of two and three-dose vaccinated recipients respectively possessed minimally protective neutralizing plasma antibody titers (IC50>1:50) against D614G. In contrast, all of the CoV2 infected-vaccinated SOTRs who received two vaccine doses possessed titers exceeding minimal protection; 12/13 exhibiting strong protection (IC50>1:600) against D614G with minimal increases provided by a third dose. Omicron was the most resistant variant: only 10% of CoV2 uninfected-vaccinated SOTRs reached the minimally protective neutralization titer, while 76% of CoV2 infected-vaccinated SOTRs exceeded this value. These results indicate that prior infection and vaccination can induce highly protective antibody responses in many SOTRs, and identify important factors (shorter time since transplantation, prednisone administration, and African American ethnicity) that limit these responses. Overall, these results suggest factors to consider in establishing optimum COVID-19 vaccination strategies in these cohorts.

As of early Feb. 2022 the cumulative number of confirmed infections caused globally by SARS-CoV-2 (CoV2) are approaching 400 million, with close to 6 million deaths, while the US alone has reported greater than 76 million cases, with over 900,000 deaths 1 . While the rapid development of various COVID-19 vaccines currently in use have helped control the spread of this virus and have greatly reduced severe complications [2] [3] [4] [5] [6] [7] [8] , the emergence of more infectious and more resistant CoV2 variants has resulted in spikes in the number of infections and deaths, which are centered in unvaccinated populations and people with impaired immune responses 1, [9] [10] [11] [12] [13] [14] [15] . The recent emergence of the highly mutated Omicron variant has accelerated these trends, since this variant is resistant to humoral immunity generated by earlier variants and vaccines, and is highly infectious even in fully vaccinated individuals [16] [17] [18] . This is particularly a problem for solid organ transplant recipients (SOTRs), who generally require immunosuppression with drugs to prevent rejection and to protect allografts. Recent reports indicate that a majority of SOTRs possess limited immunity after the standard two dose regimen of RNA-based vaccines [19] [20] [21] [22] , while a third dose of the vaccine has resulted in increasing titers of antibodies targeting the Receptor Binding Domain (RBD) as well as other subdomains of the CoV2 spike protein 23-28 . In a randomized clinical trial, 55% of SOTRs possessed the minimal protective titer of RBD antibodies 100 U/ml (15 U/ml correlates to IC50 ≥1:10) 29 after the third dose of the mRNA vaccine compared to only 18% after the second dose 30 . A recent study to evaluate the effect of a fourth dose of COVID-19 vaccines in 18 SOTRs showed positive antibody responses in subjects that were either negative or very low positive prior to receiving the latest boost 31 .

To explore COVID-19 vaccine-induced immunity in SOTRs, we used RBD-specific binding assays to quantitate the immune responses in a cohort of 51 heart and kidney transplant patients, after their second dose, and 25 SOTRs after their third dose of COVID-19 vaccines. Quantitative binding assays 32 were used to compare RBD-specific antibody levels, and neutralization assays were performed using D614G, Alpha, Beta, Gamma, Delta, Kappa, Lambda and Omicron spike pseudotyped viruses 33 to evaluate the neutralization potency of plasma antibodies against these variants, and to determine if they are below or above the minimally protective IC50 titer of 1:50 plasma dilution 34 . Approaches used in this study provide greater insights into the true protective immunity of SOTRs, while previous studies have inferred minimally protective responses based on poorly defined binding assays, or surrogate neutralization assays involving ACE2 binding competition 25,31,35-37 , which do not evaluate the neutralizing effect of non-receptor binding motif All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. infections, but ~16% had confirmed CoV2 infections prior to vaccination. Considering the requirement of a five-month interval for booster shots 38 , the blood samples were collected within five months after the second and the third vaccine shots of Pfizer and Moderna. Blood collected in sodium-heparin tubes were processed for plasma separation by centrifugation. Plasmas were aliquoted in multiple 1 ml vials and stored at -80°C for subsequent analyses for antibody binding and CoV2 neutralization activity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Codon optimized D614G, Alpha, Beta, Gamma, Delta, Kappa and Lambda spike gene sequences with 18 aa C-terminal truncations were cloned into the pCAGGS vector 40 . D614G and seven different CoV2 pseudovirus variants were made by co-transfecting the spike and pnl4.3. Luc.replasmids into HEK 293 T cells, to produce the CoV2 psV. After 48 hrs, the transfection supernatant was collected and filtered with 0.2 um filter, aliquoted, and frozen at -80°C. HuACE2-HeLa cells were infected with the CoV2 psV in DMEM media supplemented with polybrene (10 ug/ml) and infectivity was determined by reading luciferase activity in the cell-lysate after 72 hrs post-infection upon adding luciferase substrate (Britelite, PE). To determine the neutralization potency of the plasma psV dilutions giving ~100,000 RLU were used to infect Hu-ACE2-HeLA cells in the presence of titrated plasma. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

GraphPad Prism 8.0 software was used to calculate the mean, median, interquartile range (IQR) and determine suitable parametric or nonparametric tests to be applied for statistical analyses of the data. Unpaired Student t-tests or Mann-Whitney tests were performed for column statistical analysis to compare two different groups while paired t tests were performed to compare the second and third vaccine-induced antibody titers in the same subject and the neutralization potency of plasma against multiple CoV2 variants. Pearson's coefficient and Spearman r value were calculated to identify positive and negative correlations and the neutralization potency of plasma, defined as the plasma dilution, required to reduce viral signal by 50% (IC50), were calculated using One-Site Fit LogIC50 regression in GraphPad Prism 8.0. P-values were calculated at a confidence interval of 95% and are indicated as: <0.05 or *; <0.01 or **; and <0.001 or ***. An IC50 >1:50 was considered to be above the minimal protective dose, determined by antibody transfer protection experiments in macaques 34 .

A total of 51 solid organ transplant recipients (SOTRs) were recruited in this study. All the participants were vaccinated after transplantation, mostly with mRNA vaccines. A description of this cohort is provided in Table 1 , including the distributions of age, gender, race, organ transplanted, and immunosuppressive regimens administered. Eight of the participants reported COVID-19 infections before vaccination; four prior to transplantation and four after transplantation. 14 out of 51 SOTRs were recruited after their third dose of the vaccine together with 11 new post-third dose vaccinated SOTRs. A description of the post-third dose SOTR cohort is provided in Table 2 .

antibody responses compared to uninfected-vaccinated individuals. It is known that the RBD of the CoV2 Spike protein is an immunodominant target and the prime target for virusneutralizing antibodies, and we therefore focused our study on responses to this region. We used a novel RBD-gp70 fusion protein system to express native RBD as antibody targets; these proteins more efficiently recognize virus-specific antibodies than standard RBD antigens, as previously described 41 had detectable RBD antibodies with titers above the cut-off value, calculated as 3X background (AUC of 10 at OD 405nm) (Fig.1A) . Anti-RBD-IgG was detected in 61% of the SOTRs, anti-RBD-All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. IgA in 51% and anti-RBD-IgM in 39% of the SOTRs (Fig.1B) . All three anti-RBD Ig isotypes, IgG, IgM, and IgA, were detected in only 27% of the SOTRs, 50% of whom were previously infected with CoV2. There was a significantly higher level of all three anti-RBD isotypes in the infectedvaccinated group of SOTRs as compared to the uninfected-vaccinated group (Fig.1C-E) . We further examined the correlation between plasma CoV2 nucleocapsid (NC) antibodies and RBD antibodies in the infected-vaccinated and uninfected-vaccinated groups. Most of the CoV2uninfected SOTRs had low or undetectable CoV2 NC-specific antibodies, consistent with the absence of previous CoV2 infections, but did possess plasma RBD antibodies (Fig. 1G) . As expected, previously infected SOTR vaccinees had relatively high plasma titers of CoV2 NC antibodies, compared to uninfected vaccinees, and these titers correlated significantly with higher RBD-specific antibodies (r=0.79, p=0.02) (Fig.1F ).

SOTRs. 51 SOTR plasmas were assayed for their neutralization potency in HuACE2-HeLA cellbased assays against pseudoviruses containing the D614G spike and several variants, including the currently circulating variants of concerns (VOC), Delta and Omicron. We observed strong correlations between plasma RBD antibody titers and CoV2 neutralization plasma IC50 against both D614G (r =0.81, p=<0.001) and Omicron (r =0.86, p=<0.001) ( Fig. 2A-B) . Interestingly, 7/8 of the CoV2 infected-vaccinated SOTRs showed very strong neutralization titers (IC50s >1:1,000), compared to only 2/43 plasma from uninfected-vaccinated SOTRs with similar neutralization titers against D614G ( Fig. 2A) . Strong neutralization of Omicron (IC50>1:600) was observed in 6/8 two-dose vaccinated SOTRs with prior CoV2 infection while only 2/43 uninfectedvaccinated plasma reached this strength against Omicron with two doses of the vaccine. In the two-dose vaccinated cohort, only 17% (8/43) of CoV2 uninfected SOTRs reached the minimal protective titer against D614G, which decreased to 9% (4/43) against the highly resistant Omicron variant ( Fig. 2A-B) . Similar trends were observed in CoV2 infected-vaccinated SOTRs against D614G (IC50>1:1000 for 3/5 SOTRs) and Omicron (IC50>1:600 for 2/5 SOTRs) (Fig. 2C) . In three dose vaccinated cohorts, CoV2 uninfected SOTRs showed improved immunity compared to two dose cohorts, with 35% of SOTRs reaching the minimal protective titer against D614G and 15% against Omicron (Fig. 2C) .

To compare plasma neutralization resistance by multiple CoV2 variants, we selected five infectedand three uninfected-two-dose-vaccinated SOTR plasmas which displayed potent neutralization against D614G. All eight plasmas showed comparable neutralization against D614G as well as All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Alpha, Gamma, Lambda and Delta variants and remained above the minimal protective titer. A minor drop in neutralization potency of all eight plasmas were noticed against the Beta variant, but the great majority possessed a ~10 fold lower neutralization potency for Omicron compared to the other viruses (Fig. 2D) , which is consistent to what has been reported for healthy vaccinees against Omicron 16,42-44 and indirectly confirms that the majority of infected-vaccinated SOTRs and a handful of uninfected SOTRs can induce all the neutralizing antibody repertoires similar to healthy vaccinees.

We were able to obtain follow up samples from 14 SOTRs after their second and third doses of COVID-19 vaccines, with either Pfizer or Moderna, and compared their post-second and postthird dose RBD antibody titers (Fig. 2E) and plasma neutralization potencies (Fig. 2F) . Four out of 14 were also infected and showed no significant differences in RBD plasma antibody titers or neutralization potencies against the D614G virus when comparing the second and third dose. Out of the ten subjects who were CoV2 uninfected and had undetectable post-second dose RBD plasma antibodies (RBD-AUC<10), only two showed significant increases in RBD antibody titers (>100 AUC) after their third dose, and were able to cross the minimal protective IC50 threshold, while the remaining eight plasma were below the cut-off value of detectable RBD titers.

Interestingly, 3/10 plasmas from this group exhibited moderate increases in the neutralization titers (IC50 range 1:10 to 1:49) after their third dose without any detectable increase in their RBD antibody titers.

CoV2 infection in strong humoral immune responses of vaccinated SOTRs, we excluded CoV2 infected-vaccinated SOTRs (8 out of 51), to investigate factors that may contribute to lower levels of antibody production in CoV2 uninfected-vaccinated cohorts with two doses of mRNA or one dose of the J&J vaccine. We examined the effect of race, time since transplantation, type of transplanted organs, gender, and age to the levels of RBD antibody responses. Race and ethnicity are known to affect the antibody responses to rubella and influenza vaccines, which significantly induces higher titers in those of African American ethnicity as compared to those of White or Hispanic 45, 46 . Contrary to this we noticed no significant difference in plasma RBD antibody levels between Hispanic and White SOTRs, but SOTRs of African American decent had significantly lower RBD antibody titers compared to those who identified as White (p=0.003) or Hispanic (p=0.013) (Fig. 3A) .

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Time since transplantation has been associated with a higher risk of complication due to infection; SOTRs within the first three months after transplantation are known to have five times higher risks of influenza infections, due to immunosuppressive drugs 47 , and also are reported to have a lower immunologic response to influenza vaccination during the first six months after transplantation 48 .

SOTR plasma RBD antibody titers among 43 CoV2-uninfected SOTRs vaccinated at different times (0.2 to 22 years since transplantation) were analyzed. SOTRs who were vaccinated within the first 18 months (<1.5 Years) since transplantation had significantly lower RBD antibody titers compared to those who were vaccinated beyond this point (Fig. 3B) . This suggests that SOTRs in cohorts vaccinated within the first 1.5 years following transplantation have a more strongly suppressed immune system compared to those vaccinated >1.5 years post-transplantation.

SOTRs are treated with immunosuppressive drugs that alter multiple immune mechanisms (i.e., mTOR and calcineurin inhibitors, antimetabolites, and corticosteroids 49 ). All 29 KTRs and the majority of HTRs participating in this study were on maintenance immunosuppressive drugs (calcineurin inhibitors, antimetabolite Mycophenolate Mofetil, and Prednisone) while 10/22 HTRs were on the same regimen except for Prednisone. In a comparative analysis of vaccine-induced RBD antibodies between two groups (with and without Prednisone) we noticed that the addition of Prednisone negatively impacts antibody responses to COVID-19 vaccines in CoV2 uninfected SOTRs, with a lower interquartile range (IQR) of anti-RBD-IgG levels (IQR=412-1 AUC) as compared to those who were not on Prednisone (IQR=943-10 AUC) (p=0.050) (Fig. 3C) .

Immunosuppressive drugs induced nephrotoxicity is well documented 50 . Elevated serum creatinine (SCr) is one of the best clinical measures of renal function taken during routine followup of transplant recipients, and elevated SCr has been reported as a risk factor of negative responses towards vaccination 51 . We noticed a significant negative correlation between vaccine induced RBD-IgG vs SCr level (r = -0.49, p=0.008**) and RBD-IgA vs SCr level (r = -0.63, p= <0.001***), (Fig. 3D) .

These studies showed that while vaccine type, SOTR gender, age, and the type of transplanted organ (i.e., heart or kidney) had no influence on COVID-19 vaccine-induced CoV2 RBD antibody responses in SOTRs after full vaccination (Fig. 4A-D) , prior CoV2 exposure (positive predictor), ethnicity, and vaccination within 18 months (1.5 yrs) of transplantation (negative predictors) were the most dominant positive and negative factors behind the differential responses to COVID-19 vaccines after three doses. SOTRs of African American ethnicity and those who were vaccinated during the first 1.5 years since transplantation, responded poorly even after receiving a third dose of the COVID-19 vaccine (Fig. 3E) . Interestingly, all the eight CoV2-uninfected KTRs that could All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 15, 2022. ; https://doi.org/10.1101/2022.02.10.22270607 doi: medRxiv preprint not neutralize the D614G virus, even after the third dose, were vaccinated during their first 18 months (1± 0.4 years). In contrast, of 12 HTRs (one recipient was HTR+KTR) who were vaccinated during 9 ± 7 years since transplantation 50% of them had titers above the minimally protective titer for the Delta variant and 25% had protective titers against the Omicron variant (Table 2 and 3) .

This study examined the effect of a number of factors on RBD binding titers, neutralization breadth and potencies of plasma antibodies induced by COVID-19 vaccination with and without prior CoV2 infection in kidney and heart SOTRs. Since CoV2 antibodies do not necessarily possess neutralization activity, it was important to measure actual neutralization titers, rather than rely on binding correlates or surrogate virus neutralization test (sVNT) based on ACE2 binding competition, as was done in many previous studies of SOTR responses 25,31,35-37,52 . sVNTs are qualitative or semiquantitative assays for plasma neutralizing antibodies which depend on the interaction between RBD and coated human ACE2 receptor on an ELISA plate 53 . Although ACE2 competition is the basis for the majority of neutralizing antibodies induced by the current vaccines against wt-CoV2, this is not the case in RBD-mutated variants, especially Omicron. Instead, the Omicron variant can be neutralized by antibodies directed to conserved regions of the RBD core, or domains in the Spike protein outside the RBD, which are not involved in ACE2 competition.

Thus, the ACE2-competition assay does not effectively measure the activity of Omicronneutralizing antibodies such as Sotrovimab (VIR-7831), which is directed against a highly conserved target in the core of the RBD, and does not inhibit ACE2 binding 54, 55 , or NTD-specific neutralizing antibodies which have been shown to be induced by booster doses and CoV2infections in vaccinated individuals 56 . This was also evident by our findings where we noticed a moderate increase in D614G neutralization without any change in RBD antibody titers for 30% of the vaccinees when we compared post 2 nd and 3 rd dose responses. This clearly indicates the need of actual neutralization assay to accurately measure levels of protection.

The most striking observation arising from this study was the significantly higher neutralization titers of SOTRs who reported CoV2-infections prior to vaccination when compared to vaccinees who were not previously infected, which extended to the highly resistant Omicron variant. The (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 58, 59 Unfortunately, pre-vaccination bleeds were not available in this study, so we cannot distinguish whether these effects were due to residual antibody titers due to infection or whether they represent a more effective booster response to vaccination. However, in most cases sufficient time had elapsed since infection to have significantly diluted out the initial response, and thus it is more likely that stronger recall responses account for the enhanced immunity. In any case, these results clearly indicate that the transplant-related immunosuppressive regimens to which these patients were subjected to did not inhibit the ability of the combined infection-vaccination stimulus to induce an effective neutralization response that extends to a relatively resistant virus, such as Omicron, and suggest that vaccines that better induce the full range of immunological responses induced by natural infection may be further beneficial for these subjects.

We also defined demographic effects and other clinical factors which correlate with diminished protective responses. One important factor identified in this study that inhibited an effective neutralizing response was length of time since transplantation. It has been previously reported that longer post-transplantation time positively correlates with the efficacy of vaccine-induced humoral responses in SOTRs 36 . In our study, quantitation of plasma RBD antibody titers allowed the delineation of the post-transplantation time-point within which the SOTRs are more likely to have weak antibody responses to the vaccine. We found that those SOTRs who were more than 1.5 years post-transplantation had better antibody responses to the vaccine (10-1 vs 865-10 AUC RBD-IgG-IQR, p=0.002). This is consistent with earlier findings with influenza vaccines, which reported that 6 months post transplantation was an optimal time for immunogenicity, whereas we found that 18 months after transplantation was a better predictor. One possibility for this difference is that the lack of adjuvants used in mRNA based COVID-19 vaccines compared to influenza vaccines reduced the strength of the immune responses , but this question merits additional study. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Also, consistent with earlier observations, we found weaker antibody responses in African American SOTRs 60 and a negative impact of certain immunosuppressive drugs (prednisone) and drug-induced nephrotoxicity 51 on vaccine-induced immunity. Interestingly, all CoV2 uninfected KTRs exhibited low RBD antibody titers (<10 AUC) even after the 3 rd dose compared to the HTRs (100-1000 AUC), although we were not able to ascertain if this was due to organ type or time since transplantation, as we did not have matched KTR and HTR samples, in terms of time since transplantation, for comparison. These results further support the idea of critical kidney-mediated immunological functions, which are distinct from the kidney's excretory and electrolyte homeostatic functions [61] [62] [63] [64] [65] and suggests a careful management of these effects 66, 67 , and the possible benefit of modifications of immunosuppressive drugs doses immediately before and after future vaccinations, as methods for enhancing the level of vaccine-induced immunity.

We thank the study participants for their generosity and willingness to participate in longitudinal COVID-19 research studies. This work was partially supported by funding from the center for COVID-19 Response and Pandemic Preparedness (CCRP2), Rutgers University.

No potential conflict of interest relevant to this article was reported by any authors.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 15, 2022. ; https://doi.org/10.1101/2022.02.10.22270607 doi: medRxiv preprint

An interactive web-based dashboard to track COVID-19 in real time

The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

COVID vaccine excitement builds as Moderna reports third positive result

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Interim Results of a Phase 1-2a Trial of

S Covid-19 Vaccine

The single-dose J&J vaccine had 67% efficacy against moderate to severecritical COVID-19 at >/=14 d

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera

Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera

All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted

Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients

Validation of a commercially available SARS-CoV-2 serological immunoassay

Randomized Trial of a Third Dose of mRNA-1273

Vaccine in Transplant Recipients

Antibody Response to a Fourth Dose of a SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series

Highly versatile antibody binding assay for the detection of SARS-CoV-2 infection and vaccination

Characterization of a panel of novel monoclonal antibodies against the SARS CoV-2 Spike protein receptor-binding domain that possess potent neutralizing activities from a phage display semi-synthetic naïve human antibody library

Correlates of protection against SARS-CoV-2 in rhesus macaques

Diminished antibody response against SARS-CoV-2 Omicron variant after third dose of mRNA vaccine in kidney transplant recipients

Antibody Response to 2-Dose SARS-CoV-2

mRNA Vaccine Series in Solid Organ Transplant Recipients

Humoral immune responses against SARS-CoV-2 variants including 39

Highly versatile antibody binding assay for the detection of SARS-CoV-2 infection and vaccination

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Highly versatile antibody binding assay for the detection of SARS-CoV-2 infection. medRxiv. 2021. 42. WHO. Tracking SARS-CoV-2 variants

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization

Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron

Associations between race, sex and immune response variations to rubella vaccination in two independent cohorts

Race-related differences in antibody responses to the inactivated influenza vaccine are linked to distinct pre-vaccination gene expression profiles in blood

Pandemic influenza A(H1N1) virus infection in solid organ transplant recipients: impact of viral and non-viral co-infection

Vaccination in solid organ transplantation

Immune responsiveness and protective immunity after transplantation

Calcineurin inhibitor nephrotoxicity

Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus

Search of the SARS-CoV-2 Protection Correlate: Head-to-Head Comparison of Two Quantitative S1 Assays in Pre-characterized Oligo-/Asymptomatic Patients

A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline

Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner

T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all prior infected and vaccinated individuals

Cell Response Induced by SARS-CoV-2 Infection Is Boosted by the BNT162b2 Vaccine in Primary Antibody Deficiencies

No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted

Risk factors associated with poor response to COVID-19 vaccination in kidney transplant recipients

Immune cell dysfunction and inflammation in end-stage renal disease

Aspects of immune dysfunction in end-stage renal disease

Metabolic Flexibility and Innate Immunity in Renal Ischemia Reperfusion Injury: The Fine Balance Between Adaptive Repair and Tissue Degeneration

Evidence of perturbed germinal center dynamics, but preserved antibody diversity, in end-stage renal disease

The Debate about Dendritic Cells and Macrophages in the

Outcome at 3 years with a prednisone-free maintenance regimen: a single-center experience with 349 kidney transplant recipients

Drug insight: maintenance immunosuppression in kidney transplant recipients

All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted  https://doi.org/10.1101/2022.02. 10 .22270607 doi: medRxiv preprint omicron in solid organ transplant recipients after three doses of a COVID-19 mRNA vaccine. medRxiv. 2022.

CDC. COVID-19 Vaccine Booster Shots. 2022.All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table. 2 Post third dose comparison between CoV2 uninfected heart and kidney transplant patients (n=20) All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Comparison between kidney transplant recipients (KTRs) and heart transplant recipients (HTRs).All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted February 15, 2022. ; https://doi.org/10.1101/2022.02.10.22270607 doi: medRxiv preprint Table. 3 IC50 values against CoV2-WT, Beta, Delta, and Omicron variants of post-third dose plasma (n=25) All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted February 15, 2022. ; https://doi.org/10.1101/2022.02.10.22270607 doi: medRxiv preprint